These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2399525)

  • 1. [Toxic myopathy due to hypolipemic agents].
    Bourrier P; Subra JF; Chennebault JM; Spiesser R; Laine P
    Therapie; 1990; 45(4):360. PubMed ID: 2399525
    [No Abstract]   [Full Text] [Related]  

  • 2. Bezafibrate does not influence the QT interval in man.
    Olsson AG; Ekelund LG; Lang PD; Vollmar J
    J Cardiovasc Pharmacol; 1983; 5(2):341-2. PubMed ID: 6188913
    [No Abstract]   [Full Text] [Related]  

  • 3. [Rhabdomyolysis under treatment by ciprofibrate in the nephrotic syndrome].
    Baglin A; Lasserre N; Prinseau J; Lebas M
    Therapie; 1987; 42(2):247-8. PubMed ID: 3617003
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hypolipemic effect of amino acid derivatives of clofibric acid].
    Wójcicki J; Samochowiec L; Gawrońska-Szklarz B; Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1985; 42(3):305-8. PubMed ID: 4096253
    [No Abstract]   [Full Text] [Related]  

  • 5. [Plafibride--is it an effective drug as a hypolipemic agent?].
    Joven J
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999857
    [No Abstract]   [Full Text] [Related]  

  • 6. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV
    Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409
    [No Abstract]   [Full Text] [Related]  

  • 7. [Rhabdomyolysis with acute renal failure due to bezafibrate].
    Heidemann H; Bock KD
    Klin Wochenschr; 1981 Apr; 59(8):413-4. PubMed ID: 7289450
    [No Abstract]   [Full Text] [Related]  

  • 8. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
    Słowińska R; Bochenek W; Unlot J
    Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypolipemic activity of plafibride.
    Bruseghini L; Vilageliu J; Bagaria A
    Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of vascular insufficiency of the legs with plafibride].
    Lázaro Campillo T; Gesto Castromil R; de la Sierra L; Pujadas J; Villafana W; Moreno R
    Med Clin (Barc); 1984 Dec; 83(18):752-5. PubMed ID: 6521538
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic effects of bezafibrate in hyperlipidemia].
    Kunesová M; Honková M; Zeman M; Mares P; Skorepa J
    Cas Lek Cesk; 1983 May; 122(20):628-31. PubMed ID: 6342789
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapy of ischemic ulcers of the lower extremities using plafibride].
    Palou Monzo J; López-Delmás FJ
    Angiologia; 1984; 36(6):273-8. PubMed ID: 6517385
    [No Abstract]   [Full Text] [Related]  

  • 15. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W; Holm E
    Fortschr Med; 1986 Apr; 104(13):280-2. PubMed ID: 3699655
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
    Badimón JJ; Padró T; Cánovas M; Vidal M; Villaverde CA
    Methods Find Exp Clin Pharmacol; 1983 Nov; 5(9):613-7. PubMed ID: 6668971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacology and mechanism of action of etofibrate].
    Schatton W
    Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract]   [Full Text] [Related]  

  • 18. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.
    Bardosi A; Scheidt P; Goebel HH
    Acta Neuropathol; 1985; 68(2):164-8. PubMed ID: 4072624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
    Fortschr Med Suppl; 1990; 85():1-15. PubMed ID: 2338325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.